BiotechTube

Afamelanotide + Placebo

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Erythropoietic Protoporphyria

Conditions

Erythropoietic Protoporphyria

Trial Timeline

Sep 1, 2009 → May 1, 2011

NCT ID
NCT00979745

About Afamelanotide + Placebo

Afamelanotide + Placebo is a phase 3 stage product being developed by Clinuvel Pharmaceuticals for Erythropoietic Protoporphyria. The current trial status is completed. This product is registered under clinical trial identifier NCT00979745. Target conditions include Erythropoietic Protoporphyria.

What happened to similar drugs?

0 of 4 similar drugs in Erythropoietic Protoporphyria were approved

Approved (0) Terminated (0) Active (4)
🔄Placebo + DISC-1459Disc MedicinePhase 3
🔄AfamelanotideClinuvel PharmaceuticalsPhase 3
🔄Afamelanotide + PlaceboClinuvel PharmaceuticalsPhase 3
🔄Afamelanotide + PlaceboClinuvel PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (7)

NCT IDPhaseStatus
NCT04525157Phase 2Completed
NCT01605136Phase 3Completed
NCT04704713Phase 3Completed
NCT01097044Phase 2Completed
NCT00979745Phase 3Completed
NCT04425746Phase 2Completed
NCT04053270Phase 3Completed

Competing Products

8 competing products in Erythropoietic Protoporphyria

See all competitors
ProductCompanyStageHype Score
DISC-1459 + DISC-1459 + PlaceboDisc MedicinePhase 2
29
Placebo + DISC-1459Disc MedicinePhase 3
41
DISC-1459 + DISC-1459Disc MedicinePhase 2/3
39
AfamelanotideClinuvel PharmaceuticalsPhase 3
34
Afamelanotide + PlaceboClinuvel PharmaceuticalsPhase 3
34
Afamelanotide 16mg implantClinuvel PharmaceuticalsPhase 1/2
26
Afamelanotide + PlaceboClinuvel PharmaceuticalsPhase 2
29
Afamelanotide + PlaceboClinuvel PharmaceuticalsPhase 3
34